Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT06363435
Recruiting Observational

AI-based Measurements of Tumour Burden in PSMA PET-CT

NCT06363435 · tracked via the Priya Life Science Sweden tracker
Sponsor
Elin Tragardh
Phase
Observational
Started
2024-03-29
Last updated
2026-04-28

Condition(s) studied

Prostate Cancer

Investigational drug(s) / intervention(s)

AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans

AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans: Tumour burden will be automatically calculated and stored in a database. The result of the AI-based measurements will not involve the handling of the patients

Study summary

The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).

Eligibility

Sex
MALE
Min age
20 Years
Max age
120 Years
Healthy volunteers
No
Inclusion Criteria: * Patients referred to a clinically indicated 18F-PSMA-1007 PET-CT scan at Skåne University Hospital, Lund or Malmö, Sweden Exclusion Criteria: * Patients under 20 years old

Primary outcome measure(s)

  • Tumour burden (cm3) in relation to overall survival — 5-year follow-up
    Evaluate how the total tumour burden (cm3) predicts overall survival (OS). The total tumour burden will automatically be calculated by the AI-based method and will through Cox regression analysis be related to OS

Trial sites (2)

FacilityCityRegionStatus
Skåne University Hospital Lund Sweden Recruiting
Skåne university hospital Malmö Sweden Recruiting

Other trials for the same condition

Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy. Recruiting
Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project Active, not recruiting
SPCG17: Prostate Cancer Active Surveillance Trigger Trial Active, not recruiting
Prostate Cancer IRE Study (PRIS) Active, not recruiting
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06363435 on ClinicalTrials.gov ↗ ← All trials in Sweden